OliPass, Bristol-Myers deal

OliPass partnered with Bristol-Myers Squibb to discover and develop antisense medicines based on OliPass's peptide nucleic acid technology against undisclosed targets. OliPass will receive an upfront payment and research support as well as additional payments upon completion of undisclosed objectives. For each product BMS licenses, OliPass will be eligible to receive milestones and royalties. ...